PATENT CLAIM ANALYSIS

Application Number: 15904935
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.

Claim (Index 3):
The pharmaceutical composition of  claim 2 , wherein the CDK inhibitor is Roscovitine, palbociclib, or abemaciclib.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.41379
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14131183', '15115606', '15026413', '15103187', '14229221']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7670998997771985
- 35 USC 102 Novelty (BERT): 0.5140767001969597
- Combined Prediction Score: 0.7417975798191746
- Mean Citation Score: 245.182056
- Max Citation Score: 255.38828
- Similarity Product: 155.97411952883718

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test